ASU, Pfizer Partner on $5M Type 2 Diabetes Biomarker Project | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Arizona State University's Biodesign Institute will lead a study with partners at Pfizer, the Phoenix VA Healthcare System, and the University of Arizona's BIO5 Institute aimed at discovering protein biomarkers to predict cardiovascular disease in people with type 2 diabetes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.